JAMA full read comprehensive review of 'Chronic Pruritus' affecting 22%, 1% of all out pt visits - Dx algorithm - Pathophys - Rx options - Alternative Rx https://t.co/epiP8Yi1Oz https://t.co/GsORbADJZy https://t.co/K7Q6Yrx1yI

Hypertension not associated with High NSAID Doses in AxSpA At the SPARTAN meeting, Dr.Meade-Aguilar reported that amongst axSpA patients receiving NSAIDs, there was no diff in the risk for hypertension when comparing those on high vs. low dose NSAIDs. https://t.co/4XLr01wwo1 https://t.co/hdBYec6wmd

2 large 48-wk phase 3 trials (Be HEARD I/II) of Bimekizumab vs PBO in moderate-to-severe hidradenitis suppurativa shows BKZ to be safe & significantly effective (48% vs 29% & 52% vs 32%) vs PBO. https://t.co/qJykCPMn4U https://t.co/zVOTxLkW9R https://t.co/3I4eOfPYWk

No Great Options for Treating VEXAS For patients w/ VEXAS, treatment decisions are unfortunately fraught with tradeoffs between effectiveness and risk of adverse effects, a French registry study showed. https://t.co/xCQYHwgUH9 https://t.co/N5Q03izr8u https://t.co/csIixQO3sJ

Biologic-treated Psoriasis has Less Progression to Psoriatic Arthritis A single center study demonstrates that biologic treatment of PsO significantly reduces the likelihood of PsA development; suggesting a role for more aggressive treatment of PsO. https://t.co/VHk2KEsP8d https://t.co/1r4zVAzrMw

ACR Website to Support PCPs The American College of Rheumatology recently launched Rheumatology for Primary Care, a new resource for PCP and APP offering them expanded support and guidance to identify rheumatic diseases in their patients. https://t.co/yZbpG3598O https://t.co/S4oYNMrdqt

Colchicine prophylaxis w/ allopurinol (“start-low go-slow” 100mg escalation strategy), is best used in pts w/ gout flare in month prior to allopurinol. Longer prophylaxis may be required w/ ongoing flares in 1st 6mos of allopurinol if T2T not achieved https://t.co/qWUwrAcCJZ https://t.co/6S7Y6p7BnF

Ramosetron,a 5-HT3 recept antagonist used for post-op N/V,t has been used for adjunctive pain Rx & IBS. An 80 FM pt DBRCT tested PBO vs Ramosetron (.3 mg/day IV x5d). @d5 had signif better VAS pain (1.18  vs 0.54, p< 0.05), but didnt persist till day 28 https://t.co/0ABduv8Nlq https://t.co/WGlxIhst1o

Anakinra in COVID showed mixed (often negative) results. But this Turkish retrospective observational study comparing standard of care to IV anakinra in severe COVID pts. IV ANAK had less thromboembolic event (5% vs 12.3%, p = 0.038), better survival https://t.co/4webWJKEfB https://t.co/85GnCd6N8O

Forbes on the future of CAR-T cell therapy - A Gamechanger For Autoimmune Diseases. Innovation, costs, more trials and regulatory differences for autoimmune (vs cancer) patietns? https://t.co/1Yg40HPTzh https://t.co/NqCwEzmZ1g